376 related articles for article (PubMed ID: 20609184)
1. How does short-term low-dose simvastatin influence serum prohepcidin levels in patients with end-stage renal disease? A pilot study.
Li XY; Chang JP; Su ZW; Li JH; Peng BS; Zhu SL; Cai AJ; Zhang J; Jiang Y
Ther Apher Dial; 2010 Jun; 14(3):308-14. PubMed ID: 20609184
[TBL] [Abstract][Full Text] [Related]
2. Effect of fluvastatin on serum prohepcidin levels in patients with end-stage renal disease.
Arabul M; Gullulu M; Yilmaz Y; Akdag I; Kahvecioglu S; Eren MA; Dilek K
Clin Biochem; 2008 Sep; 41(13):1055-8. PubMed ID: 18571502
[TBL] [Abstract][Full Text] [Related]
3. Influence of erythropoietin therapy on serum prohepcidin levels in dialysis patients.
Arabul M; Gullulu M; Yilmaz Y; Eren MA; Baran B; Gul CB; Kocamaz G; Dilek K
Med Sci Monit; 2009 Nov; 15(11):CR583-7. PubMed ID: 19865058
[TBL] [Abstract][Full Text] [Related]
4. Serum pro-hepcidin level and iron homeostasis in Japanese dialysis patients with erythropoietin (EPO)-resistant anemia.
Shinzato T; Abe K; Furusu A; Harada T; Shinzato K; Miyazaki M; Kohno S
Med Sci Monit; 2008 Sep; 14(9):CR431-7. PubMed ID: 18758412
[TBL] [Abstract][Full Text] [Related]
5. Effects of simvastatin on high-sensitivity C-reactive protein and serum albumin in hemodialysis patients.
Chang JW; Yang WS; Min WK; Lee SK; Park JS; Kim SB
Am J Kidney Dis; 2002 Jun; 39(6):1213-7. PubMed ID: 12046033
[TBL] [Abstract][Full Text] [Related]
6. Type of renal replacement therapy and residual renal function may affect prohepcidin and hepcidin.
Malyszko J; Malyszko JS; Kozminski P; Mysliwiec M
Ren Fail; 2009; 31(10):876-83. PubMed ID: 20030521
[TBL] [Abstract][Full Text] [Related]
7. Does hepcidin affect erythropoiesis in hemodialysis patients?
Eleftheriadis T; Kartsios C; Liakopoulos V; Antoniadi G; Ditsa M; Papadopoulos C; Anifandis G; Skirta A; Markala D; Stefanidis I
Acta Haematol; 2006; 116(4):238-44. PubMed ID: 17119323
[TBL] [Abstract][Full Text] [Related]
8. [Serum prohepcidin and other iron metabolism parameters in healthy adults].
Zekanowska E; Boinska J; Kwapisz J; Kedziora-Kornatowska K; Porzych K; Ratajczak M
Przegl Lek; 2011; 68(2):82-6. PubMed ID: 21751515
[TBL] [Abstract][Full Text] [Related]
9. Serum prohepcidin levels correlate with hepatic iron stores in chronic hepatitis C patients.
Lin TJ; Liao LY; Chou JM; Liu SO; Wang CK
Hepatogastroenterology; 2009; 56(93):1146-51. PubMed ID: 19760959
[TBL] [Abstract][Full Text] [Related]
10. Role of prohepcidin, inflammatory markers and iron status in resistance to rhEPO therapy in hemodialysis patients.
Costa E; Pereira BJ; Rocha-Pereira P; Rocha S; Reis F; Castro E; Teixeira F; Miranda V; do Sameiro Faria M; Loureiro A; Quintanilha A; Belo L; Santos-Silva A
Am J Nephrol; 2008; 28(4):677-83. PubMed ID: 18354252
[TBL] [Abstract][Full Text] [Related]
11. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
12. Atorvastatin and simvastatin in patients on hemodialysis: effects on lipoproteins, C-reactive protein and in vivo oxidized LDL.
van den Akker JM; Bredie SJ; Diepenveen SH; van Tits LJ; Stalenhoef AF; van Leusen R
J Nephrol; 2003; 16(2):238-44. PubMed ID: 12768071
[TBL] [Abstract][Full Text] [Related]
13. Association of prohepcidin and hepcidin-25 with erythropoietin response and ferritin in hemodialysis patients.
Kato A; Tsuji T; Luo J; Sakao Y; Yasuda H; Hishida A
Am J Nephrol; 2008; 28(1):115-21. PubMed ID: 17943020
[TBL] [Abstract][Full Text] [Related]
14. [Pro-hepcidin, its relation with indicators of iron metabolism and of inflammation in patients hemodialyzed treated or not with recombinant erythropoietin].
Barrios Y; Espinoza M; Barón MA
Nutr Hosp; 2010; 25(4):555-60. PubMed ID: 20694291
[TBL] [Abstract][Full Text] [Related]
15. Effect of hydroxymethylglutaryl-CoA reductase inhibitors on low-density lipoprotein cholesterol, interleukin-6, and high-sensitivity C-reactive protein in end-stage renal disease.
Soliemani A; Nikoueinejad H; Tabatabaizade M; Mianehsaz E; Tamadon M
Iran J Kidney Dis; 2011 Jan; 5(1):29-33. PubMed ID: 21189431
[TBL] [Abstract][Full Text] [Related]
16. Serum prohepcidin and hepcidin in hemodialyzed patients undergoing iron therapy.
Malyszko J; Malyszko JS; Mysliwiec M
Kidney Blood Press Res; 2009; 32(4):235-8. PubMed ID: 19713706
[TBL] [Abstract][Full Text] [Related]
17. Short-term effect of simvastatin treatment on inflammatory parameters in peritoneal dialysis patients.
Sezer MT; Katirci S; Demir M; Erturk J; Adana S; Kaya S
Scand J Urol Nephrol; 2007; 41(5):436-41. PubMed ID: 17853009
[TBL] [Abstract][Full Text] [Related]
18. IL-6 is an independent risk factor for resistance to erythropoiesis-stimulating agents in hemodialysis patients without iron deficiency.
Won HS; Kim HG; Yun YS; Jeon EK; Ko YH; Kim YS; Kim YO; Yoon SA
Hemodial Int; 2012 Jan; 16(1):31-7. PubMed ID: 22284696
[TBL] [Abstract][Full Text] [Related]
19. IL-18 is involved in vascular injury in end-stage renal disease patients.
Porazko T; Kúzniar J; Kusztal M; Kúzniar TJ; Weyde W; Kuriata-Kordek M; Klinger M
Nephrol Dial Transplant; 2009 Feb; 24(2):589-96. PubMed ID: 18775894
[TBL] [Abstract][Full Text] [Related]
20. Low serum levels of prohepcidin, but not hepcidin-25, are related to anemia in familial amyloidosis TTR V30M.
Beirão I; Almeida S; Swinkels D; Costa PM; Moreira L; Fonseca I; Freitas C; Cabrita A; Porto G
Blood Cells Mol Dis; 2008; 41(2):175-8. PubMed ID: 18544472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
